Peri-Implant and Peri-Prosthetic Fractures: Epidemiology, Morbidity, Mortality, Treatment and Outcome Analysis
Condition(s) studied
Study summary
This study supports Spanish data collection and analysis on Periprosthetic and Peri-implant fractures of the upper and lower limb. Treatment and clinical management of this fractures are complex and goes along with complications. There will be more than 70 hospitals providing information. This study will provide evidence on which is the best treatment for every unique patient. This will help trauma surgeons and geriatricians to provide better treatments, to improve health care in our society, reducing mortality, morbidity, improving functional outcomes, and reducing costs, which in turn will be advances in trauma care.
Eligibility
Primary outcome measure(s)
- Mortality — Up to 12 months
Rate of mortality at anytime from fracture diagnose up to 12 months - Fracture classification — Pre-operatively (Day -1)
Fracture classification using the UCS for periprosthetic fractures, and the adapted H. Broggi classification for peri-implant fractures. Number of patients in each classification group - Treatment — Post-operatively (Day +1)
Number of patients treated with fixation or revision and fixation or implant removal
Trial sites (7)
| Facility | City | Region | Status |
|---|---|---|---|
| Mutua Universitaria de Tarrasa | Barcelona | Spain | Recruiting |
| Althaia, Xarxa Assistencial Universitària de Manresa | Barcelona | Spain | Recruiting |
| Hospital Clinic | Barcelona | Spain | Recruiting |
| Hospital Universitario Vall d´Hebrón | Barcelona | Spain | Recruiting |
| Hospital de Jove | Gijón | Spain | Recruiting |
| Hospital Universitario 12 de Octubre | Madrid | Spain | Recruiting |
| Hospital Clínico Universitario de Valladolid | Valladolid | Spain | Recruiting |
More Hospital Clínico Universitario de Valladolid trials in Spain
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT04663893 on ClinicalTrials.gov ↗ ← All trials in Spain